Literature DB >> 30203936

The pathologist's role in the detection of rare variants of bladder cancer and analysis of the impact on incidence and type detection.

Guglielmo Mantica1,2, Alchiede Simonato3, Danelo E Du Plessis4, Massimo Maffezzini5, Aldo F De Rose5, André van der Merwe4, Carlo Terrone5.   

Abstract

BACKGROUND: Histology is one of the most important factors determining the prognosis of bladder cancers and rare variants are generally associated with decreased disease specific survival compared to pure transitional cell carcinomas. We believe that rare bladder cancer variants are likely underdiagnosed in the absence of a dedicated uro-pathologist in many centers. The objective of this study is to evaluate the contribution of a dedicated uro-pathologist on the identification of rare bladder cancer variants.
METHODS: We retrospectively analyzed the clinical and histological records of all patients which underwent a radical cystectomy and lymph node dissection between January 2000 and September 2015. The sample was divided in two groups: Group A, consists of patients who underwent radical cystectomy in the absence of a dedicated uro-pathologist at our institution, whereas the Group B consists of patients who underwent surgery when a dedicated uro-pathology service was available. We then evaluated the impact of a dedicated uro-pathologist on rare variants detection.
RESULTS: One hundred thirty-seven out of 551 (24.9%) of patients who underwent RC had at least one rare variant. In Group A 38/238 (16%) of patients showed a rare variant, while 99/313 (31.6%; P<0.001) in group B. Furthermore, the diagnosis of sarcomatoid variant was statistically significantly less common in group A (P=0.0026). The concordance between final radical cystectomy histology and previous transurethral resection of bladder tumor (TURBT) histology was poor in both groups (overall 50.4%).
CONCLUSIONS: The presence of a dedicated urological anatomical pathologist is of paramount importance and significantly increases the detection rate of non-transitional cell carcinoma bladder cancer types, but it does not increase the concordance rate between histological diagnoses in TURBT and radical cystectomy specimens.

Entities:  

Mesh:

Year:  2018        PMID: 30203936     DOI: 10.23736/S0393-2249.18.03175-2

Source DB:  PubMed          Journal:  Minerva Urol Nefrol        ISSN: 0393-2249            Impact factor:   3.720


  6 in total

1.  Evaluation of the Extent of Variant Histology in Urothelial Carcinoma as a Predictive Marker of Clinical Outcomes After Radical Cystectomy.

Authors:  Akinori Minato; Hirotsugu Noguchi; Ryosuke Moriya; Katsuyoshi Higashijima; Gosuke Yamasaki; Rieko Kimuro; Yoshitaka Hasegawa; Ikko Tomisaki; Naohiro Fujimoto
Journal:  Cancer Diagn Progn       Date:  2021-07-03

2.  The Accuracy of Transurethral Bladder Resection in Detecting Bladder Cancer Histological Variants and Their Prognostic Value at Radical Cystectomy.

Authors:  Giovanni La Croce; Richard Naspro; Marco Finati; Federico Pellucchi; Mario Sodano; Michele Manica; Michele Catellani; Andrea Gianatti; Marco Roscigno; Luigi Filippo Da Pozzo
Journal:  J Clin Med       Date:  2022-01-22       Impact factor: 4.241

3.  Bladder cancer histological variants: which parameters could predict the concordance between transurethral resection of bladder tumor and radical cystectomy specimens?

Authors:  Guglielmo Mantica; Stefano Tappero; Stefano Parodi; Nataniele Piol; Bruno Spina; Rafaela Malinaric; Federica Balzarini; Marco Borghesi; André Van Der Merwe; Nazareno Suardi; Carlo Terrone
Journal:  Cent European J Urol       Date:  2021-09-09

Review 4.  The Role of Novel Bladder Cancer Diagnostic and Surveillance Biomarkers-What Should a Urologist Really Know?

Authors:  Rafaela Malinaric; Guglielmo Mantica; Lorenzo Lo Monaco; Federico Mariano; Rosario Leonardi; Alchiede Simonato; André Van der Merwe; Carlo Terrone
Journal:  Int J Environ Res Public Health       Date:  2022-08-05       Impact factor: 4.614

5.  Intravesical Bacillus Calmette-Guérin Treatment for T1 High-Grade Non-Muscle Invasive Bladder Cancer with Divergent Differentiation or Variant Morphologies.

Authors:  Makito Miyake; Nobutaka Nishimura; Kota Iida; Tomomi Fujii; Ryoma Nishikawa; Shogo Teraoka; Atsushi Takenaka; Hiroshi Kikuchi; Takashige Abe; Nobuo Shinohara; Eijiro Okajima; Takuto Shimizu; Shunta Hori; Norihiko Tsuchiya; Takuya Owari; Yasukiyo Murakami; Rikiya Taoka; Takashi Kobayashi; Takahiro Kojima; Naotaka Nishiyama; Hiroshi Kitamura; Hiroyuki Nishiyama; Kiyohide Fujimoto
Journal:  Cancers (Basel)       Date:  2021-05-26       Impact factor: 6.639

6.  Intravesical Therapy for Non-Muscle-Invasive Bladder Cancer: What Is the Real Impact of Squamous Cell Carcinoma Variant on Oncological Outcomes?

Authors:  Guglielmo Mantica; Francesco Chierigo; Rafaela Malinaric; Salvatore Smelzo; Francesca Ambrosini; Martina Beverini; Giovanni Guano; Alberto Caviglia; Lorenzo Rigatti; Aldo Franco De Rose; Alessandro Tafuri; Davide De Marchi; Franco Gaboardi; Nazareno Suardi; Carlo Terrone
Journal:  Medicina (Kaunas)       Date:  2022-01-07       Impact factor: 2.430

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.